Statements (155)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:ABBV
|
| gptkbp:activities |
Janus kinase inhibitor
inhibits Janus kinase enzymes |
| gptkbp:approves |
gptkb:ulcerative_colitis
gptkb:2020 gptkb:FDA gptkb:rheumatoid_arthritis atopic dermatitis |
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Rinvoq
|
| gptkbp:category |
gptkb:unknown
gptkb:C |
| gptkbp:class |
Janus kinase inhibitor
|
| gptkbp:clinical_trial |
Phase 3
approximately 85% enhanced quality of life treatment of rheumatoid arthritis treatment of ulcerative colitis treatment of atopic dermatitis moderate to severe rheumatoid arthritis Rinvoq for atopic dermatitis Rinvoq for rheumatoid arthritis Rinvoq for ulcerative colitis improved skin clearance reduced itch severity |
| gptkbp:contraindication |
active infections
history of thrombosis hypersensitivity to upadacitinib |
| gptkbp:developed_by |
gptkb:Abb_Vie
|
| gptkbp:dissolved |
soluble in DMSO
slightly soluble in water |
| gptkbp:dosage_form |
gptkb:tablet
once daily 15 mg 30 mg |
| gptkbp:duration |
long-term
as prescribed by a healthcare provider |
| gptkbp:education |
important
importance of adherence to therapy monitoring for side effects do not crush or chew tablets take with or without food recognizing signs of infection regular follow-up appointments required report any signs of infection immediately |
| gptkbp:effective_date |
2020-08-01
|
| gptkbp:formulation |
extended-release
film-coated tablet 15 mg tablet 30 mg tablet |
| gptkbp:has_ability |
15 mg
30 mg |
| https://www.w3.org/2000/01/rdf-schema#label |
Rinvoq
|
| gptkbp:indication |
moderate to severe rheumatoid arthritis
moderate to severe ulcerative colitis moderate to severe atopic dermatitis |
| gptkbp:ingredients |
gptkb:upadacitinib
|
| gptkbp:interacts_with |
immunosuppressants
live vaccines CY P3 A4 inducers CY P3 A4 inhibitors |
| gptkbp:invention |
2028
2028-12-31 |
| gptkbp:is_monitored_by |
liver function tests
lab tests regular follow-ups complete blood count symptom assessment lipid levels |
| gptkbp:is_used_for |
gptkb:ulcerative_colitis
gptkb:rheumatoid_arthritis atopic dermatitis treatment of rheumatoid arthritis treatment of ulcerative colitis treatment of atopic dermatitis |
| gptkbp:lifespan |
approximately 6 to 14 hours
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Abb_Vie_Inc.
gptkb:Abb_Vie |
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Rinvoq gptkb:2020 gptkb:2021 gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:pharmacokinetics |
oral bioavailability
metabolized by liver half-life of 9-14 hours inhibition of JA K1 reduction of inflammatory cytokines |
| gptkbp:population |
adults
pediatric patients adults and children 12 years and older |
| gptkbp:previous_name |
gptkb:upadacitinib
|
| gptkbp:price |
high
varies by insurance coverage approximately $2,000 per month without insurance |
| gptkbp:products |
gptkb:Xeljanz
gptkb:Olumiant |
| gptkbp:provides_information_on |
ACR guidelines
recommended for moderate to severe cases included in dermatology treatment guidelines |
| gptkbp:regulatory_compliance |
approved for ankylosing spondylitis
approved for atopic dermatitis approved for psoriatic arthritis approved for rheumatoid arthritis |
| gptkbp:requires |
available online
prescription only available on manufacturer's website |
| gptkbp:research |
ongoing
|
| gptkbp:safety_features |
thromboembolic events
liver function tests complete blood count risk of liver problems risk of thrombosis risk of blood clots risk of serious infections lipid levels risk of certain cancers risk of malignancies risk of malignancy |
| gptkbp:scholarships |
gptkb:stock_market_index
educational resources for patients available patient assistance programs |
| gptkbp:side_effect |
heart attack
fatigue headache nausea stroke gastrointestinal perforation infections blood clots thrombosis increased risk of infections malignancy risk serious infections gastrointestinal perforations elevated liver enzymes increased liver enzymes malignancies |
| gptkbp:social_structure |
C17 H20 N6 O2
|
| gptkbp:storage |
room temperature
protected from moisture |
| gptkbp:traded_on |
gptkb:Rinvoq
|
| gptkbp:treatment |
varies by individual
improvement in quality of life reduce symptoms improve function may take weeks to see effects prevent joint damage reduction in disease activity |
| gptkbp:type_of_care |
once daily dosing
|